| Assessment Status | Rapid review complete |
| HTA ID | 21035 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 30/08/2021 |
| Rapid review completed | 23/09/2021 |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.
